Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Assault On Drug Marketing Tactics Becomes Drug-Specific On Capitol Hill

Executive Summary

Pharmaceutical firms avoided a moratorium on direct-to-consumer television ads in the FDA Amendments Act, but that victory seems of little comfort now as Congress undertakes a wide-ranging probe of industry marketing practices

You may also be interested in...



Academic Detailing Bill Could Be Interim Step To Comparative Effectiveness

Congressional critics of pharmaceutical marketing practices launched another volley in their battle to curb industry influence on prescribers with the July 31 introduction of legislation that would create a federally-supported "academic detailing" program

Academic Detailing Bill Could Be Interim Step To Comparative Effectiveness

Congressional critics of pharmaceutical marketing practices launched another volley in their battle to curb industry influence on prescribers with the July 31 introduction of legislation that would create a federally-supported "academic detailing" program

Will Schering-Plough’s Vytorin Headache Prove Contagious?

The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)

Related Content

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel